HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Lumateperone

HCID 21302490
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
313368-91-1
Standard SMILES
CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12
InChIKey
HOIIHACBCFLJET-SFTDATJTSA-N
Molecular formula
C24H28FN3O
Average molar mass
393.5 g/mol
Monoisotopic mass
393.22164069

Overview

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia. The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.

Names & identifiers

Preferred name
Lumateperone
IUPAC
1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one
English name
Lumateperone
Molecular formula
C24H28FN3O
Molecular weight
393.5

Names & synonyms

lumateperone313368-91-1ITI-722lumateperonaITI007ITI 00770BSQ120691-Butanone, 1-(4-fluorophenyl)-4-((6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalin-8(7H)-yl)-lumateperonum1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-RefChem:57789DTXCID801510464
Show more names
1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-oneLumepperoneLumiperidoneLumateperone ITI-722ITI-722 lumateperoneLumateperone, 10 mM in DMSO313368-91-1Lumateperone(ITI-007)
1-(4-fluorophenyl)-4-((10R,15S)-4-methyl-1,4,12-triazatetracyclo(7.6.1.0^(5,16).0^(10,15))hexadeca-5(16),6,8-trien-12-yl)butan-1-oneDTXSID401026211ITI-007Lumateperone [USAN]MFCD285021611-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one1-(4-Fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one

Properties

Computed structural properties

XLogP
3.8
Topological polar surface area
26.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
5
Rotatable bonds
5
Heavy atoms
29
Formal charge
0
Complexity
593

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Unknown

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents

FDA approved drugs -> Active ingredient

Physicochemical properties

Boiling point
556.4 · 556.4±50.0 °C(Predicted)
Density
1.26 · 1.26±0.1 g/cm3(Predicted)
pka
9.1 · 9.10±0.20(Predicted)
form
Oil
color
Colorless to light yellow
InChIKey
HOIIHACBCFLJET-SFTDATJTSA-N
SMILES
C(C1=CC=C(F)C=C1)(=O)CCCN1C[C@@]2([H])C3=CC=CC4=C3N([C@@]2([H])CC1)CCN4C
FDA UNII
70 BSQ12069 · 70BSQ12069
Symbol(GHS)
7 · GHS07
Signal word
Warning

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Hepatotoxicity · 1 item

In preregistration controlled trials, ALT elevations arose in 2% of patients receiving lumateperone compared to less than 1% of placebo controls. The elevations, however, were usually mild, transient and typically resolved without dose modification or drug discontinuation. In preregistration trials, there were no instances of severe hepatic adverse events, discontinuations because of liver related events or episodes of clinically apparent liver injury with jaundice. Since its approval and more widescale use, there have been no published reports of liver injury with symptoms or jaundice attributed to lumateperone therapy, but clinical experience with its use has been limited.

Adverse EffectsThe adverse effects associated with the administration of lumateperone are mild to moderate. At the FDA-approved dosage of 42mg/day, the most common side effects are somnolence, sedation, fatigue, and constipation.
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H319-H335
Precautionary statements
P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein BindingLumateperone is approximately 97.4% plasma protein bound.
Pharmacodynamics · 1 item

Lumateperone, also known as ITI-007, is an atypical antipsychotic that has proven to be effective in the treatment of schizophrenia. Lumateperone's receptor binding profile is unique, allowing it to target schizophrenia related symptoms while minimizing adverse effects. In contrast to other second generation antipsychotics such as [lurasidone] and [brexpiprazole], lumateperone behaves as a partial agonist and as an antagonist at pre and postynaptic dopamine (D2) receptors respectively. Patients with moderate or severe hepatic impairment (Child-Pugh class B or C) tend to have higher plasma concentrations of lumateperone than those with normal hepatic function. For this reason, patients with moderate or severe hepatic impairment should receive half the recommended daily dosage.

Mechanism of Action · 1 item

There is much to learn about the pathophysiology of schizophrenia; however, dopamine abnormalities, specifically in the prefrontal and mesolimbic brain regions, are consistent in people with schizophrenia. In addition to dopamine, other neurotransmitters such as serotonin, glutamate, GABA and acetylcholine are thought to play a role. Lumateperone is unique among second generation antipsychotics based on its target profile and dopamine D2 receptor occupancy. Unlike other antipsychotics, lumateperone has partial agonist activity at presynaptic dopamine (D2) receptors, resulting in reduced presynaptic release of dopamine, and antagonistic activity at postsynaptic dopamine (D2) receptors. These characteristics allow lumateperone to efficiently reduce dopamine signaling. Lumateperone also targets dopamine (D1) receptors, and a useful secondary result of D1 activation is increased glutamatergic N-methyl-D-aspartate (NMDA) GluN2B receptor phosphorylation. This is significant since NMDA mediated glutamate signaling appears to be impaired in patients who have schizophrenia. Finally, lumateperone is capable of modulating serotonin by inhibiting serotonin transporters (SERT), and by behaving as a 5-HT2A receptor antagonist.

Related reactions

7 records
New reaction record
HRID 350795 reaction equation
HRID 350795As product
HRID 1267054 reaction equation
HRID 1267054As product
HRID 1486961 reaction equation
HRID 1486961As reactant
HRID 1624927 reaction equation
HRID 1624927As product
HRID 1764812 reaction equation
HRID 1764812As product
HRID 1789968 reaction equation
HRID 1789968As product
HRID 1876771 reaction equation
HRID 1876771As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
313368-91-1、313369-37-8
PubChem CID
21302490
DTXSID
DTXSID201101217
ChEMBL
CHEMBL3306803
UNII
70BSQ12069
Nikkaji
J3.323.976I
Hazard statements
315 · H315-H319-H335
Precautionary statements
264 · P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501
Biological Half-Life
Lumateperone's half life is reported to be between 13 to 18 hours. The reported half lives of the metabolites ICI200161 and ICI200131, are 20 and 21 hours respectively.
Metabolism/Metabolites · 1 item

Lumateperone is extensively metabolized. The carbonyl side chain is reduced by ketone reductase to produce the primary active metabolite. Cytochrome P450 3A4 enzymes metabolize lumateperone to 2 metabolites: the active N-desmethylated carbonyl metabolite (IC200161) or the N-desmethylated alcohol metabolite (IC200565).

FDA Pharmacological Classification · 6 items

70BSQ12069

LUMATEPERONE

Established Pharmacologic Class [EPC] - Atypical Antipsychotic

Lumateperone is an Atypical Antipsychotic.

LUMATEPERONE

Atypical Antipsychotic [EPC]

Absorption, Distribution and Excretion · 4 items

Lumateperone is able to permeate multidrug resistance protein 1 (MDR1) and is very lipophilic at a pH of 7.4, which are characteristics that allow the antipsychotic to be absorbed in the small intestine and the blood brain barrier. Tmax occurs 3-4 hours after oral administration.

Due to it's molecular weight, virtually all unchanged lumateperone is excreted in the feces. Lumateperone's metabolites are very water soluble which is a property that allows for complete elimination. Approximately 58% of a lumateperone dose can be recovered in the urine, while 29% can be recovered in the feces.

The volume of distribution of lumateperone is approximately 4.1 L/Kg after intravenous administration.

Lumateperone's clearance is estimated to be 27.9 L/hour.

Applications · 2 items

DescriptionLumateperone is a novel antipsychotic agent with a unique mechanism of action with high 5-hydroxytryptamine 2A(5-HT2A) blocking activity. A Phase 2 study in treatment of insomnia revealed strong evidence of efficacy, with no impairment of next-day cognition.

UsesLumateperone was a drug developed for the treatment of schizophrenia. May have applications in bipolar depression.

Upstream & downstream products

Upstream raw materials

4'-fluoro-4-iodobutyrophenone1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-(6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline4-Fluorophenylmagnesium bromide4-Chloro-4'-fluorobutyrophenoneWaterPotassium iodideToluene1,4-DioxaneHydrochloric acid